Regenerative Medicine Co. Posts 38% Sales Gain in 2021
  (3/2/22)
Organogenesis Holdings Inc. shares traded 23% higher after the company reported FY/21 financial results that included a 46% YoY increase in revenue from its Advanced Wound Care products sales. More >

This Year Should Be Catalyst Rich for Oncology Pharma Co.
  (3/1/22)
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report. More >

Co. to Rebound After Q4/21 Sales Down Due to Virus Surge
  (3/1/22)
The 2022 outlook for a cancer detection and therapy solutions company is positive given its focus on dermatology and implementing new commercial strategies, noted an Oppenheimer report. More >

Primary Care Operator to Open 40 New Centers in 2022
Source: Streetwise Reports  (3/1/22)
Shares of a Medicare-focused and AARP endorsed primary care facility operator traded 27% higher after the company reported FY/21 financial results that included a 64% YoY increase in capitated revenue. More >

Biotech to Take Novel Cancer Drug to Market in H1/22
Source: Streetwise Reports  (2/28/22)
This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases. More >

Super Computers Create Powerful Drugs for Alzheimer's
Source: Streetwise Reports  (2/25/22)
A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins. More >

Pharma Co. Posts 364% YOY Revenue Increase in Q421
Source: Streetwise Reports  (2/25/22)
Aerie Pharmaceuticals Inc. shares traded 30% higher after the ophthalmology-focused pharmaceutical company reported Q4/21 and FY/21 financial results and announced the appointment of a new Chief Medical Officer. More >

Imaging Diagnostics Co.'s Shares Rise 35% on FY21 Earnings
Source: Streetwise Reports  (2/24/22)
Lantheus Holdings Inc. shares traded to a new 52-week high after the firm reported Q4/21 and FY/21 financial results that included a 25.3% increase in annual revenue. The firm also advised that the FDA approved the sNDA for its isolator-based drug manufacturing facility for diagnostic ultrasound enhancing agent DEFINITY® for patients in the U.S. with suboptimal echocardiograms. More >

Q1 Results of Cannabis Firm Down YoY
  (2/24/22)
Despite a dampened Q1 FY22 performance and an uncertain future, parts of a cannabis firm's story remain attractive, warranting a Market Perform rating, noted a Noble Capital Markets report. More >

Beauty Health Provider Posts 118% Increase in FY22 Sales
Source: Streetwise Reports  (2/23/22)
Shares of Beauty Health Co. traded 32% higher after the company that is credited with creating the category of hydradermabrasion reported Q4/21 and FY/21 financial results outlining significant improvements in sales, margins and adjusted earnings. More >

HC Staffing Firm Posts Triple-Digit Revenue Gains in Q421
Source: Streetwise Reports  (2/19/22)
Shares of a health care professional staffing and services company traded 12% higher after the company reported Q4/21 financial results that included a 116% YoY increase in revenue and a 1,149% YoY increase in net income. More >

Cannabis Cos. Expected to Post Better Revenues As of Q2/22
Source: Streetwise Reports  (2/18/22)
Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report. More >

Pharma Co. Decreases BMI by 14.3% in Obesity Trial
Source: Streetwise Reports  (2/18/22)
Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS). More >

Dialysis Equip. Co. Posts Record FY21 Sales
Source: Streetwise Reports  (2/17/22)
Shares of a wireless mobile dialysis equipment maker traded 15% higher after the company reported FY/21 financial results highlighting a 105% YoY increase in revenue to $102.6 million. More >

Small-Cap Drug Co. Fights Clinicians' COVID Stress
Source: Streetwise Reports  (2/15/22)
In a recent interview with Streetwise Reports, Cybin Inc.'s General and IP Counsel Robert Mino explained the company's position at the forefront of mental health treatment via psychedelics. "This sector has the potential to improve the human condition on a massive scale." More >

Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences
  (2/14/22)
Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share. More >

Canadian Hedge Fund CIO Talks Top 2022 Prospects
Source: Streetwise Reports  (2/9/22)
AlphaNorth Asset Management was recently recognized with multiple performance awards at the 2021 Alternative IQ Canadian Hedge Fund Awards. The AlphaNorth Partners Fund won first place for its five-year annualized return gaining 40.35% for the period. The fund also placed second for its three-year return and third for its one-year return. Streetwise Reports sat down with CIO Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022. More >

Mental Health Co. Brings Psychedelics to the World
Source: Streetwise Reports  (2/9/22)
In Citi's Jan. 25, 2022 Psychedelic Call Series broadcast, Novamind CEO Yaron Conforti and Chief Medical Officer Dr. Reid Robison discussed how the company is increasing people's access to psychedelic therapies for mental health disorders. More >

Digital Medical Co.'s Earnings Are Just What the Doctor Ordered
Source: Streetwise Reports  (2/9/22)
Doximity Inc. shares traded 25% higher after the digital medical platform provider used by 80% of all physicians in the U.S. reported Q3/22 financial results that included a 67% YoY increase in revenue. More >

Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table
Source: Vision and Value  (2/8/22)
In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19. More >

Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?
Source: Streetwise Reports  (2/7/22)
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal. More >

Drug Re-Purposing Co. Pursues Novel Stroke Therapies
Source: Streetwise Reports  (2/3/22)
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke. More >

Co. Focused on Pipeline of Drug Candidates
  (1/31/22)
In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report. More >

Biopharma Co. to Resubmit BLA to FDA for Type 1 Diabetes
Source: Streetwise Reports  (1/31/22)
Shares of Provention Bio Inc. traded 29% higher after the company reported that following its Type B meeting and conversations with the U.S. FDA, it is now planning to resubmit a Biologics License Application for delay of clinical type 1 diabetes in at-risk individuals. More >

Neuroscientist With Research Program Joins Biotech's SAB
Source: Streetwise Reports  (1/29/22)
ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program. More >